# Protein kinase C family (PKC)

Source: https://onco.cc/targets/pkc/  
OnCo record `pkc` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Protein kinase C is a family of signalling enzymes; the AML drug midostaurin started life as a PKC inhibitor and still hits the family alongside FLT3.

## Summary

The protein kinase C family (PRKCA and its relatives) transmits signals from calcium and diacylglycerol to growth, survival and secretion pathways. Midostaurin (PKC412) was developed as a PKC inhibitor and gained approval in FLT3-mutant acute myeloid leukaemia and systemic mastocytosis through its FLT3 and KIT activity; PKC remains among its listed targets. PKC-beta inhibitors such as enzastaurin were tested in lymphoma without success.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Symbol: PRKCA
- Class: kinase
- Biology: Serine/threonine kinases in conventional, novel and atypical subfamilies; PKC-alpha also drives resistance and vascular permeability signalling.
- Where found: Ubiquitous; Inhibited by midostaurin in AML and mastocytosis

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Protein_kinase_C
- UniProt P17252: PRKCA: https://www.uniprot.org/uniprotkb/P17252/entry
- HGNC:9393 PRKCA: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9393
- ChEMBL target CHEMBL2093867: https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2093867

## Connected records

- targets: [FLT3](https://onco.cc/targets/flt3/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Midostaurin](https://onco.cc/drugs/midostaurin/)

---
JSON: https://onco.cc/api/v1/entities/pkc.json